The representation is being given by South Chemists & Distributors Association (SCDA) which says that the proposed acquisition needs to be rejected by the CCI
Allowing PharmEasy to acquire Thyrocare which has a wide presence in the diagnostics market would give the company an unfair advantage, said the SCDA
Besides calling epharmacies illegal, the SCDA also claimed that the only reason for the adoption of epharmacies is that they offer discounts
Healthtech unicorn PharmEasy’s proposed acquisition of Thyrocare, which is subject to regulatory approval, is likely to face a legal challenge at the Competition Commission of India (CCI) from a group of chemists and druggists. The representation is being given by South Chemists & Distributors Association (SCDA) which says PharmEasy’s proposed acquisition of Thyrocare Technologies needs to be rejected by the CCI.